-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 Elu7ASZ/az1EMWLSDghFKEOJjFivtlgEhQHdv3xCkmSfYQfMJYm/tBpptckG7/uZ
 0oKvvKETSNRutX81dyoUrQ==

<SEC-DOCUMENT>0001129928-09-000045.txt : 20090715
<SEC-HEADER>0001129928-09-000045.hdr.sgml : 20090715
<ACCEPTANCE-DATETIME>20090715105515
ACCESSION NUMBER:		0001129928-09-000045
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20090715
FILED AS OF DATE:		20090715
DATE AS OF CHANGE:		20090715

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ONCOLYTICS BIOTECH INC
		CENTRAL INDEX KEY:			0001129928
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-31062
		FILM NUMBER:		09945133

	BUSINESS ADDRESS:	
		STREET 1:		1167 KENSINGTON CRES NW SUITE 210
		STREET 2:		CALGARY ALBERTA CANADA T2N 1X7
		CITY:			ALBERTA CANADA
		STATE:			A0
		ZIP:			00000
		BUSINESS PHONE:		4036707380

	MAIL ADDRESS:	
		STREET 1:		210 - 1167 KENSINGTON CRES NW
		CITY:			CALGARY
		STATE:			A0
		ZIP:			T2N 1X7
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>form6-k.htm
<DESCRIPTION>6-K FORM
<TEXT>
<html>
<head>
    <title>form6-k.htm</title>
<!-- Licensed to: Oncolytics Biotech Inc.-->
<!-- Document Created using EDGARizer 5.1.0.0 -->
<!-- Copyright 1995 - 2009 Thomson Reuters. All rights reserved. -->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
<div>
<hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="4">
<hr style="MARGIN-TOP: -10px; COLOR: #000000" noshade size="1"></div>
<div>&#160;</div>
<div>&#160;</div>
<div>
<br>&#160;</div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">SECURITIES AND EXCHANGE COMMISSION</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Washington, D.C. 20549</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman">Form 6-K</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Report of Foreign Private Issuer</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant to Rule&#160;13a-16 or 15d-16</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">of the Securities Exchange Act of 1934</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For the month of&#160;July 2009</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Commission File Number 000-31062</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman">Oncolytics Biotech Inc.</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">(Translation of registrant&#8217;s name into English)</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Suite&#160;210, 1167 Kensington Crescent NW</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Calgary, Alberta, Canada T2N 1X7</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">(Address of principal executive offices)</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate by check mark whether the registrant files or will file annual reports under cover Form&#160;20-F or Form&#160;40-F.</font></div>
<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
<tr>
<td align="left" valign="bottom" width="38%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td align="left" valign="bottom" width="38%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td></tr><tr>
<td valign="top" width="38%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Form&#160;20-F&#160;&#160;&#160;<font style="DISPLAY: inline;" face="Wingdings">&#254;</font></font></div></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td valign="top" width="38%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Form&#160;40-F&#160;&#160;&#160;<font style="DISPLAY: inline;" face="Wingdings">o</font></font></div></td></tr></table></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate by check mark if the registrant is submitting the Form&#160;6-K in paper as permitted by Regulation&#160;S-T Rule&#160;101(b)(1):&#160;&#160;&#160;<font style="DISPLAY: inline;" face="Wingdings">o</font></font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Note: </font>Regulation&#160;S-T Rule&#160;101(b)(1) only permits the submission in paper of a Form&#160;6-K if submitted solely to provide an attached annual report to security holders.</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate by check mark if the registrant is submitting the Form&#160;6-K in paper as permitted by Regulation&#160;S-T Rule&#160;101(b)(7):&#160;&#160;&#160;<font style="DISPLAY: inline;" face="Wingdings">o</font></font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Note: </font>Regulation&#160;S-T Rule&#160;101(b)(7) only permits the submission in paper of a Form&#160;6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is
incorporated, domiciled or legally organized (the registrant&#8217;s &#8220;home country&#8221;), or under the rules of the home country exchange on which the registrant&#8217;s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant&#8217;s security holders, and, if discussing a material event, has already been the subject of a Form&#160;6-K submission or other Commission filing on EDGAR.</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule&#160;12g3-2(b) under the Securities Exchange Act of 1934.</font></div>
<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
<tr>
<td align="left" valign="bottom" width="38%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td align="left" valign="bottom" width="38%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td></tr><tr>
<td valign="top" width="38%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Yes&#160;&#160;&#160;<font style="DISPLAY: inline;" face="Wingdings">o</font></font></div></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td valign="top" width="38%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">No&#160;&#160;&#160;<font style="DISPLAY: inline;" face="Wingdings">&#254;</font></font></div></td></tr></table></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">If &#8220;Yes&#8221; is marked, indicate below the file number assigned to the registrant in connection with Rule&#160;12g3-2(b):&#160;&#160;&#160;82&#160;-&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
<tr>
<td valign="bottom" width="7%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">EXHIBIT</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">NUMBER</font></div></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td align="left" valign="bottom" width="69%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">DESCRIPTION</font></div></td></tr><tr>
<td align="left" valign="top" width="7%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td align="left" valign="top" width="69%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td></tr><tr>
<td valign="top" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">99.1</font></div></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td align="left" valign="top" width="69%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">News Release Dated&#160;July 15, 2009 -&#160;Oncolytics Biotech&#174; Inc. Research Collaborators Present Glioma Reovirus Research at ASV Annual Meeting</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div></td></tr></table></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt">
<br></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">SIGNATURES</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
<tr>
<td align="left" valign="bottom" width="38%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td align="left" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td align="left" valign="bottom" width="36%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td></tr><tr>
<td align="left" valign="top" width="38%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td align="left" colspan="3" valign="top" width="39%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Oncolytics Biotech Inc.</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Registrant)</font></div></td></tr><tr>
<td align="left" valign="center" width="38%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td align="left" valign="center" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td align="left" valign="center" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td align="left" valign="center" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td align="left" valign="center" width="36%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td></tr><tr>
<td align="left" valign="top" width="38%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td align="left" valign="top" width="36%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td></tr><tr>
<td align="left" valign="center" width="38%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td align="left" valign="center" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td align="left" valign="center" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td align="left" valign="center" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td align="left" valign="center" width="36%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td></tr><tr>
<td align="left" valign="top" width="38%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Date:&#160;&#160;July 15, 2009</font></div></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td align="left" valign="top" width="2%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">By:</font></div></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td align="left" valign="top" width="36%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">/s/&#160;&#160;Doug Ball</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Doug Ball</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Chief Financial Officer</font></div></td></tr></table></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt">
<br></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
<br>
<br></body>
</html>


</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit99.htm
<DESCRIPTION>NEWS RELEASE
<TEXT>
<html>
<head>
    <title>exhibit99.htm</title>
<!-- Licensed to: Oncolytics Biotech Inc.-->
<!-- Document Created using EDGARizer 5.1.0.0 -->
<!-- Copyright 1995 - 2009 Thomson Reuters. All rights reserved. -->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
<div style="DISPLAY: block; TEXT-INDENT: 0pt">
<br></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font><font id="TAB2" style="LETT
ER-SPACING: 9pt">&#160;&#160;&#160;</font><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;</font><img src="exhibit-992.jpg" alt=""><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;
</font><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;</font><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font><font 
id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font></font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt">
<div style="DISPLAY: block; TEXT-INDENT: 0pt">
<div>
<hr style="COLOR: black" align="left" noshade size="1" width="100%"></div></div></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: -18pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">FOR IMMEDIATE RELEASE</font>
<br></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Oncolytics Biotech<font style="DISPLAY: inline; FONT-SIZE: 10pt">&#174;</font> Inc. Research Collaborators Present</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Glioma Reovirus Research at ASV Annual Meeting</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt">
<br></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">CALGARY, AB, --- July 15, 2009</font> &#8211;Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY)</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">announced today that a poster presentation by Dr. Jacqueline Parker <font style="DISPLAY: inline; FONT-STYLE: italic">et al</font>. entitled &#8220;<font style="DISPLAY: inline; FONT-STYLE: italic">Anti-Tumor Activity of Reovirus is Synergistically Enhanced in Combination with Temozolomide and Low Dose Irradiation in Primary Patient Glioma
Xenografts Resistant to Treatment with Either Therapy Alone</font>&#8221; was made yesterday at the 28<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">th</font> American Society for Virology (ASV) Annual Meeting.&#160;&#160;&#160;The meeting is being held in Vancouver, British Columbia, from July 11-15, 2009.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt">
<br></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8220;These results support the strategic direction we&#8217;re taking with the REOLYSIN<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">&#174;</font> clinical program,&#8221; said Dr. Matt Coffey, Chief Operating Officer for Oncolytics.&#160;&#160;&#8220;The future program for REOLYSIN, including our pivotal program,
is focused on exploiting these underlying drug synergies.&#8221;</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The poster covers preclinical work using reovirus in combination with low dose irradiation (IR) and temozolomide (TMZ).&#160;&#160;A panel of glioma cell lines and primary patient glioma explant cells were tested for susceptibility to reovirus, IR, TMZ, or a combination of these therapies <font style="DISPLAY: inline; FONT-STYLE: italic">in
vitro</font>.&#160;&#160;The combination index analyses revealed moderate to strong synergy in primary patient glioma cells treated with reovirus plus IR and TMZ <font style="DISPLAY: inline; FONT-STYLE: italic">in vitro</font>.&#160;&#160;&#160;This effect was also seen <font style="DISPLAY: inline; FONT-STYLE: italic">in vivo</font> in flank tumor xenografts from primary patient tumors resistant to reovirus therapy alone.</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The investigators concluded that the data supports the use of reovirus in combination with standard radiation and chemotherapies for the treatment of malignant glioma in humans.</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">The poster will be available on the Oncolytics website at </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; TEXT-DECORATION: underline">www.oncolyticsbiotech.com</font><font style="DISPLAY: inline; FONT-SIZE: 10pt"> at a later date.</font></font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">About Oncolytics Biotech Inc.</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics.&#160;&#160;Oncolytics&#8217; clinical program includes a variety of Phase I/II and Phase II human trials using REOLYSIN, its proprietary formulation of the human reovirus, alone and in combination with radiation
or chemotherapy.&#160;&#160;For further information about Oncolytics, please visit <font style="DISPLAY: inline; TEXT-DECORATION: underline">www.oncolyticsbiotech.com</font>.</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the implication of the abstracts and materials presented at this meeting with respect to REOLYSIN, the Company&#8217;s expectations related to the results of
trials investigating delivery of REOLYSIN, and the Company&#8217;s belief as to the potential of REOLYSIN as a cancer therapeutic, involve known and unknown risks and uncertainties, which could cause the Company&#8217;s actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of REOLYSIN as a cancer treatment, the success and timely completion
of clinical studies and trials, the Company&#8217;s ability to successfully commercialize REOLYSIN, uncertainties related to the research and development of pharmaceuticals, uncertainties related to the regulatory process and general changes to the economic environment. Investors should consult the Company&#8217;s quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned
against placing undue reliance on forward-looking statements. The Company does not undertake to update these forward-looking statements, except as required by applicable laws.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt">
<br></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">FOR FURTHER INFORMATION PLEASE CONTACT:</font></div>
<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="25%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Oncolytics Biotech Inc.</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Cathy Ward</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">210, 1167 Kensington Cr NW</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Calgary, Alberta T2N 1X7</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Tel: 403.670.7377</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Fax: 403.283.0858</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">cathy.ward@oncolytics.ca</font></font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div></td>
<td align="left" valign="top" width="26%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">The Equicom Group</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Nick Hurst</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">325, 300 5<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">th</font> Ave. SW</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Calgary, Alberta T2P 3C4</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Tel: 403.538.4845</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Fax: 403.237.6916</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">nhurst@equicomgroup.com</font></font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div></td>
<td align="left" valign="top" width="28%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">The Investor Relations Group</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Erika Moran</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">11 Stone St, 3rd Floor</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">New York, NY&#160;&#160;10004</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Tel:&#160;&#160;212.825.3210</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Fax:&#160;&#160;212.825.3229</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">emoran@investorrelationsgroup.com</font></font></div></td></tr></table></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">-30-</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
<br></body>
</html>


</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>exhibit-992.jpg
<TEXT>
begin 644 exhibit-992.jpg
M_]C_X``02D9)1@`!`0$`>`!X``#_X0!F17AI9@``24DJ``@````$`!H!!0`!
M````/@```!L!!0`!````1@```"@!`P`!`````@`!`3$!`@`0````3@``````
M``!X`````0```'@````!````4&%I;G0N3D54('8U+C`P`/_;`$,``@$!`0$!
M`@$!`0("`@("!`,"`@("!00$`P0&!08&!@4&!@8'"0@&!PD'!@8("P@)"@H*
M"@H&"`L,"PH,"0H*"O_;`$,!`@("`@("!0,#!0H'!@<*"@H*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"O_``!$(`%$!
M4P,!(@`"$0$#$0'_Q``?```!!0$!`0$!`0```````````0(#!`4&!P@)"@O_
MQ`"U$``"`0,#`@0#!04$!````7T!`@,`!!$%$B$Q008346$'(G$4,H&1H0@C
M0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I*C0U-C<X.3I#1$5&1TA)2E-45597
M6%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJ
MLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X
M^?K_Q``?`0`#`0$!`0$!`0$!`````````0(#!`4&!P@)"@O_Q`"U$0`"`0($
M!`,$!P4$!``!`G<``0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B
M<M$*%B0TX27Q%Q@9&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G
M:&EJ<W1U=G=X>7J"@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>X
MN;K"P\3%QL?(R<K2T]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@`,`P$`
M`A$#$0`_`/W\HHK-\7>+_#?@/P[>>+O&&N6NFZ7IUNT]]?WLPCB@C49+,QZ"
M@"^\R*,YS6-XS^)7@#X=:;_;'Q`\::3HEIN"BYU;48[>,DG`&Z0@<GBO@?XX
M_P#!4/X]?'_XF7'P%_8!\#273.[1Q^)A:B6XN%'WI8DD`CMXASB27)/!PO0U
M?`'_``1G^+/Q8U)/'7[7W[0M]+?7`,ES9:=,U[=*6W;E-S<$HI'R'Y49<Y'(
M`:O.EC959<N'@Y>>R-/9V^)V/JIO^"E'[#$;M&_[2/A_<K$'#2$?F$YK9\$_
MMT_L@_$?5#HG@W]H/PQ<W>Z-5@EU%8&=G;:JKYNW>Q)QA<FO)-/_`."+/[$M
MO8PV]WIOB:YE2)5DN7\12*TK`<L0@"@GK@`#G@5A_$7_`((@_LK>(-%^S^`/
M$?B3PY?IN,=VU]]MC)(P-\<HY`Y^ZRGGDT<^96^&/WL3]EW/LRTO[.^@6ZL[
ME)8F'R2QN&5OH1P:E#*W0YK\KO'/[.W[>?\`P3$U4?$;X,>/KCQ)X+MI`UXE
MHDCVR0K("%N[-B1&IW']Y$>-SG<F>?J_]AO_`(*:_"[]K".'P1XBMH?#?CAE
M=O[$>5FAO53&9+:0@;C@Y,1^==K'Y@-U72QU.53V=1.,NSZ^@2IM*ZU/J.BD
M1MRAL=12UW$!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!
M1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`-D/R$?J:_,3]L3XT_$
M[_@I%^TC!^Q]^SL[P^&]!OIAJE])<XM[UX9%62]F"]88CQ&O)9F!QD@+]=_\
M%*OVA-2_9U_90UWQ-X<N1#K6L,FCZ-+E@T<T^0TBD#ADB65QD@90#.2!7`_\
M$<OV;K'X5?LTQ?%;4[/&M^.F%XTDL?S1V*EEMT'^RPS+GG=YB^@QYN+<L17C
MAUMO+T[&D?<7,>X_LM_LJ_"S]D[X>1^!/AII"B2;;+J^JS$M<:A<!0#([$DA
M<YVIG:HX'J?3Z`,#%%>A"$:<5&*LD9MMN["BBBJ`;,JNA1E!!&""*_/S_@I?
M_P`$[/#WA'PW+^U/^RYH$V@Z[H5VM_KFGZ&SQJ8EQFZMXXQ^ZEC;$C%2H*AF
M(R.?T%J"_L[:_MGL[R!)8949)8I4#*ZD8*D'@@C@@USXBA"O#EEOT?8J,G%W
M1\W?\$TOVTT_:U^#[6?BJ3'B[PPD5MX@+;0+T,I\N[0*!@/M;(P,.K`9&#7T
MQ7Y8>.O!\W_!-?\`X*;^'=7\%3/#X0\6W:-'91LK;;&[F$4]L4&WY8I</'TP
M!&,G#Y_4R)MV>.AK#`5ISA*G/XHNS'.*3NNH^BBBN\@****`"BBB@`HHHH`*
M***`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HH
MHH`****`/SI_X+NZW=7=W\,/APT:+:W<U_=O<*#YBL#!#@<XQB4GIU`[<5]_
M>`_"NG>!O!VE^#=(`%KI>G06MN!&J_)'&J`X4`#(&>!BOS\_X+L:9J$'B?X5
M^,Y;?&FV_P#:%O-<[QA9#);2;<?>/RHQX';UP#^AWAW5[#7M#M-;TN;S;6\M
M8Y[:7:1OC=0RM@@$9!!P:\W#I/'UK^7W6-)?PXEVBBBO2,PHHHH`****`/@/
M_@O)X/T.7X4>!_'S6V-3MO$<NGQS*`,P2V[RLIXR</`A'/&6_O5]C?LWZYJW
MBGX!>"/%&O7AN+W4?"&FW-Y,4"^9*]LC,V%``R23P!7R-_P7CU33XO@3X)T6
M2\C%W-XN>XAMBXWO%':2H[@>BM+&">V\>M?6/[+D=Q9_LU_#ZRO+62&:'P3I
M22Q2H59&%I&""IY!&.AKSJ3MCZGHOU*_Y=1/*_\`@IY^T]\4OV4?@;I?Q"^$
MS::NHWGB>&PE.IV9G3RFM[B0X4,N#NC7G/K7FG[$/_!3OQ%X^\=#X%_M9V-A
MH7B74O*G\,ZM:Q^39:E%,JO#'RS`,ZL&C<,5D#`##8#6/^"Z#;OV4_#XZ?\`
M%=V_/_;I=UB^+_\`@GKX8_:X_8<^&'C+P@8-*\?:5\/-,_LS4C\B7R);(5MI
MR.V?NOU0G^Z2*RJO%?6W[-_"MNY7N\EF?3/[9?Q'^(OPA_9H\6_%#X77^G0:
MSH&F&]A?5+5IH6CC=6E4HI!+-'O"\X#$$UQ__!-']I'XE?M3?LZS?$_XK/I[
M:FGB.ZL5_LVT,,?E1I$5^4LW.7;G-?'VA_MW^/K[]EWXG?L6?M6V-[9^-=+\
M)7UKI&J:@");HQ1$_9K@GK*$&4ER1*N.2Q!?Z$_X(B#=^QG<<_\`,Z7_`/Z*
MMZ*6*]OC(J+=K.Z\[@X*$+-'UKKNO:/X6TJZUWQ!J4%G96=N\UW=W4PCCAC4
M99V9N%``Y)KXX'[??[1G[67C74/`7[`'PMTZ33-(N`NI>/?&#,+,X;A8XEY&
M]02N[+%23M7&3Z7_`,%4/"_COQ?^Q-XPTGP!')+<)';7&H6D%L99+BSCN$>5
M%503D!0^1CA#R*\K_P""(7CGX:2?LZZEX`TC68E\3P^(+F^UC3)KM#*\;+$D
M=Q'&/F$6U40DC'F*_/(K2O5D\6J*=DU?_AF))*-SO;KP-_P5BLO.U.U^.GPC
MNY!"/*T]_#EVD;,NX[0V<J6R%))(``P!@Y]M^!MS\=;SP:+S]H/2_#=CKLD[
MDV?A:6>2WAB'"@R3'+N<$G`4#('.,GL57<H;-*/D/UKKI45!WN_ON2W<X']I
M']HSX:_LP?#6[^)WQ.U<P6L'[NSM(2#/?W!&4@A4_><X^@&6)`!-?.GP@^/?
M_!1S]L#2(OBC\'/#'@3X=^#[F%AI;^*EGU"XOV#[2X\O9M3(;!*KG'&X$,>5
M_P""[G@GQ;J_PC\&>-=,GO)-(TG79H]5M8;=FBB::("*XD8<)M*M&,C!,W4'
M&?HK_@GMX\\&_$/]D#P)J?@FVMK:WLM`AT^ZLK=L_9;F!1'+&<@8.X%NF"'!
M!(()XW.=7'.E)M)*_K_PQ25H<QP7BJ'_`(*S>`=&D\66/B7X5^-'L\.WAJPT
M>ZM)KQ>A"2R2!01G=@D9VX!YJ_\`L6_\%*?AU^UCKLGPXU/PK>^&/&5I:R37
M&CW;B2&81D"3R9."2I/*,H8`$\@$CZ4D^7'N*_)W]EZ$>/?^"PE]K_PGO7M]
M,B\8:U?7%Q',9EFM%682_.B@;)7;*@C`$B+EN"9KU*F&J04)7YG;74<4I7/U
MF5@XR*^-_P!@+]MCXY?M'?M-?$3X4?$J?1VTCPPEVVEC3]-:&4&.^,"[VWL&
M^3V'/-?8\8^7=ZU^;G_!(?'_``W-\9^W[J__`/3L:WQ4YQQ%%)VNW?[B4ERL
M_26JFO6FIWVCW5KHNJ+8W<ENZVUXUN)1#(0=KE"0&P<'&1G&,BK3-M[4,-RE
M<UW$GP,/^"BO[3/[*W[3!^$'[=NA:2WAN^&-/\2>'M*DAC\LOA;M<N_F1]!)
M']^/DX./F^SO&'QG^&'@7X7W'QD\3^,["W\-06`O&U@7`>%X6&49"N?,+9`4
M+DL2`,FN>_:E_9:^&'[5GPRG^'/Q(L#E0TNDZM`@^T:;<[2!-$3^14_*PX/M
M^8O[.?[.OQ%^/O[1,O[`/Q%^,^H/X+^'NKZE>W-G;2MY<OV>=()!`&R4+LPQ
MNR(PTC*-S'/D5*E?"SY'[RE\/KYFEE)770^MOV7/VN?VN_VU_CAJ'B/X9:)I
M/A?X0:3?".2_U;26FO;T(>88W\P+YK]6P"L0(!+-C/TU\=-,^.NK^!OLW[/G
MB?0-(\0B\C87GB6QDN+7R.?,4I&0VX\8/08-;OP_^'W@_P"%OA"P\!^`M!M]
M,TC3+=8+*RM4VI&@_F2<DD\DDDDDUM5W4J,U2M.5V]_\D0VN:Z/C/]HGQO\`
M\%//V<O@YK?QI\3?%_X5W]CH4,<EQ9V'AB[$L@>:.(!=T@'5P>?2J/[+WQ3_
M`."FG[5?P>L?C1X2^*WPNTRQO[FYACM-2\,71E5H9GB8G9(1@E<CV/->K?\`
M!4W_`),/^(1_Z<;3_P!+K>L#_@CJN?V#_#?/_,5U3_TMEKCY9+&JGS.UK[E_
M9O8]A_9ZT3]I'1M!OQ^TMXW\,ZUJ<EV#8-X6TR6V@A@"#AO-)9G+9YZ8`]Z\
MW_X*9_M)_$[]E?\`9[M_B9\*&T]-3E\26UB6U.T,\?E/',S?*&7G*+SGUKZ)
M5=O>OCK_`(+A?\F=6/\`V.UE_P"B+FNG$2E2PLG%ZI$P^(]C_8-^-/CG]H3]
MEOPS\7OB/)9MK&J_:Q=FPMC#%^[NYHEVJ6;'RHO<\UT_[0W[0?PV_9G^&UY\
M4OBAK0M;*V&RWMX\-/>SD$I!"F?G=L?0`$D@`FO+?^"31S^P7X(/J=1_].%Q
M7C/_``79\*?$#5_A+X-\4:#9W$V@:/K-P=;\G<4AFDC1;>:0`$`#$R!B1AI%
M'\7&3K3IX%5=W8.7WK'0?#?]JG_@H+^V5)#XK_9L^$OAOP%X,61A'KOCGS;E
M]14LX#Q+&%#*-@!V@@%B`[8Q7=OHG_!5SPX?[6/C;X/>)A'Q_8S:;?60ER<;
MO.!.W;G.,<XQ77?\$]?$OPZ\2_L>^!/^%9WL<EE8>'K>TNX5FWO;W:(/M".-
MQ*MYN]MI.<,.@KVNKHTG4IJ3FW?L]`O9V,3P`OC?_A%+%_B1_9HUPVRMJ:Z.
M)!:K*>66+S"6*CID\G&<#.!\O_MO?\%)/$?[/'QMT3]G3X3_``VLM6\2:J+-
MI+[7;MXK*+[3*8XD'E_,Q)!+,2`HQPW./KNO*OVDOV/?@'^U5IL>F?%[P1'=
M75M$4L-9LY/(O;0$Y(CE7G&>=K;ESR5-:8B%:5&U*5F)-)W9YA<?#W_@JIKE
M]!K\G[0GPNT@PDR1Z+:>&[B:WE\SK%-(_P`[",9VLA7<1SP:Z3X+7_\`P46M
M_&=EH7QYT/X8S>'XYYO[0UW1+R[2[FC&[R_+@(VJ2=@^8GC/>O*)_P#@FK^U
M'\-+-[?]G'_@H%XKL+:(0O;Z5XB+S1ET(&#(KD)'L4`((B#C!X/'GUI_P4&_
M;0_98_:&T_\`9P_:=TKP]XV:ZO[6/[?H:!+MX+F5E21!$%3?EE/EO&IPO?<&
MKC]K[!IU%)7=M[HOEYMC]&`,#%%%%>L9GRM_P5U^`]U\9/V2K_7=)TTW.J^#
MKI=7MEB4%S;JI6Y4<'_EDS/@=?+`S6G_`,$I_C_9?'#]DK1+"\U4S:UX21=&
MUA)"3)B,?N)"2Q+;X=GS9Y97Z8P/I"_M+>^M)+2[A22*6,I)'(N5=3P01W!&
M17Y:^*+7XC_\$?OVO)/&&DZ6VJ_#;QE--Y&GV\Q'FV@<-Y)'W5N;??\`(3\K
M(Q&1N.WS,3_LN*CB/LO27EV9I'WHV/U0R#T-%<W\*OBIX$^,W@FQ^(/PX\0V
MNJ:3J$(>"YM9U?:?XHWVD[74\,IY!&#725Z,9*2NMC,****H`I&95ZFE)P"?
M05\K_P#!1G_@H3H'[*O@I_"'P]U/3=0\>Z@#%;V+3K(=)C9"?M4\8YQC&Q#C
M<2#RJFLJU:%&'-(:3D[(^8_VZ-=C_;B_X*-^%/V;_!R2W6E>'KM-+U.:&1FC
MSO$U])@,H`CC7RRP(8E"!GY<_I[I]I'8VR6D";8XD5(QG.%`P!GO7QE_P28_
M8MU3X3>&+C]I/XMVSGQAXOMB]G'="3SK&SE82,90X!$\K`.V>0,#/WA7VI7'
M@:=1J56IHY._RZ%U))NRZ'D'[97[(WAO]LOX<67PS\5>+=0T6VL=9CU&.ZTR
M.-I'=(I8PI\P$`8D)]>*[KX._#BR^#WPN\/?"O3=2FO+?P]HUMIT%U<`"25(
M8P@=@O`)`R<<5\K_`+=__!17XK_LR_MM_"#]D3X>>#M+N+?XF>&M=U2\UZZ\
M,:MK5Q9-IZQLJ1V.F9FE#[R"W1.IX!KK/^"?_P#P4,/[6GCGXC_!#Q]X<M-"
M\:_#;6([>[L?L]YI\^IV,J*\.H+IFH11WEI$P=%S(&1FSLD;!"]JI04^?J9F
M]^V/_P`$[?@S^V/=V/B'Q+=7>@Z]8;8QKVCQQ^=<6XSB&57!5P"<J2-R\@'!
M(KKOV._V5_#W['WPFD^$WACQ5?:Q;2:O/?\`VS48HTDW2*@*XC`&!L&._->J
MDX&:^</VG_VYM9^`_P"V[^SK^R'I7P_M=0A^-VI^(8M0UNXO61M+ATS3?M0\
MN,+AWD=XQDD`*K<$D8E8>BJOM$O>&VVK,^C3$K`JV"",$$5\Q_%3_@E9^S_X
MT\8M\3/ACK&O?#?Q([EWU+P5?_9D=F8%R8C\J[L'(0J#N)()KZ>KQG]O_P#;
M"L/V#?V4?%G[4>I_##6_%\/AFS63^Q-"`$DKNZQJTLC`K;VZE@TL[96)`S$-
MC%.K1IUE::N";6QR=K^PM\9UNXGO_P#@H1\69[=9%\^!;BT0R)D;EW"+*DC(
MSVSGM7J?P"^`.G?L_:!=^&='^)'B_P`0VEU<":,>+];_`+0DMVQAA'(R!PIX
M)4DC/3&3GY\_:(_;D_:T_91_9SO?VT/BG\$?`&M^`=,T:UU37M"\*^,KG^U]
M*MI)HD<P32VQM]5(20N`/LH)4*I?=NKZM\%>++#QUX4TSQCI5M<Q6NK:=!>V
ML=Y;M#,L<L:NHD1AE'`894\@Y!Y%*G0ITW=`VV2>*O"VA>--!N_"_B?1[;4-
M.U"V:WO;*[B#QS1,,,C*>""*^:K;_@ESX4^'WB&?6/V:OV@O'WPTM;R,"^TG
M0-46>WE<;?G`N`Y!^4=23Z$#BOI+QBOBJ3P[>0^"+C3XM7:V<:=+JL#RVRS$
M?*9$C969,]0&!/3(KXY^`?[:G[;'QG_;P^,?[%=W9?"NQ/P8MO#EUJ.OQ:5J
M3_VM%JELUP4CB-U^X>-4*Y9G#$YP`"*)T*527-):@FT=K?\`_!/7XR^)-%DT
M#QG_`,%"?BG?6ER"EY;PR6\*RQ[LA<A=R\8!(/)SP`<5ZQ^SE^R-\"_V6-"D
MT7X0>#(K*6XB1+_5+AS->7FWH996Y(R20HPHSP!7IBMN&<=Z\\_:Y^,>J?L[
M_LL_$?X_:'H]OJ-YX(\"ZMKUKI]V[+%<R6EG+<+&Y7D*QC`)'(!-*.'I0=T@
M;;/1,`=!7Q[X=_X)*VG@7XD:U\4OAC^UAX[\,:IKEW<RW<ND1VR?)-*96BY0
M[E#'C.3P#UYK:_8N_:O_`&BOVAY?#>I?$2VT:PMM3\.1ZIJEA:?";Q1IJQ&2
M%66*'4=26.WEVO(G.T%U#%5&,CZH!R,TZM"E6:<UML";6Q\T_P##"GQO_P"D
MC'Q:_P"^[/\`^-U[[X%\,7W@WPIIWAB]\1WVL2V%E'!+JNIS;[B[=5PTLA_O
M,<DXX&<#`KRO]O;]M;PK^PI\%K;XK^)?"=UK,VJ^(;'0M&M5G^RV@OKN98HG
MO;UU,5A;`G+SR<#`"AW95/0_!S4/VH]5UBXU7XY1_#RPTNX20Z;I'A"XO;V>
M'YQL9[V=84F!0$G;;QX+`9(4EG"C"F_=$>F5\^_!7_@G_P"#O@K^U#XH_:CT
MKQ_JU]J/B@WYN=*NX(5MX/M5PD[;2HW':4"C)Z'FOH*O`OV]_P!LK4?V,M.^
M%VN6O@.Z\06OCGXLZ;X3U2#3=/N;R\MK:YM[J5KBWM[96DGD0VZ_(%)VEC@X
MISI0J-.2O;5#3:/?:*^.O'/_``5+6#_@H-\!?V-_A[\+M8;2OBS;^)9-;UKQ
M=X0UC1+BP;3;`7,0M4OK>%;@.25?&[9QG&X9^Q:T$<)^TE\"]+_:0^"VN?!7
M6]=N=-M-=ABCFOK.-6EB"31R@J'RIR8P.?6J'[*7[..B_LI_!O3_`(,>'/$E
MYJ]I87-S,E]J"(LKF:9I2"$`7`+8&!VKTJBLO8P]IS]=@"O)OVPOV4O#_P"V
M)\*XOA3XG\57^C6T.KPZ@MYIL4;R%HTD4)B0$8/F'/?BO6:^:OV4/VX/%O[0
M7[<7[2/[*.M>!]-T[3O@AJOAZTTG5;2>1I]274=/:Z=IE;Y4*,NT;>HZU<X1
MJ1<9;,#U7]F'X`Z-^S'\%='^"V@>(+O5+31S.8KZ^1%ED\V>28[@@`&"Y''8
M5V/B+PUH?BS0[OPUXETJWOM/OK=X+RSNX1)%-$PPR,IX(([5?KY?_;G_`&U_
MCI^S5\=_A=\*_@G^S_;_`!"_X2[2?$>K:[I$&I&WU22STJ.S=XM.##RI;IA=
M%ECE9%?RM@=68&DJ<5%16R`J7/\`P2K^'WA'Q[<>/?V</C7XU^&$EZC"\T_P
MS?JUNY)_A64':HYPN2!GY=M:;?\`!/\`^(.N_P#$N\?_`+=_Q>U;2VYFL8=6
MALV=ARI$L,8=<'!P.O3IFN8_9K_X*E:/^U;^VYI/[/7PF\`2MX(U/X+3^,?^
M$KU..:WO8-5AU2"RN-&FM70?9Y[<2JTR,2RF6/@*P+?7]9+"T%HD5S2.<^&/
MP]3X7>!--\!6?B;5]7ATRW\F+4-?OC<W<JY)'F2D`N0#@$C.`*\C^.'[`OAO
MXV>-]3^(TGQZ^)GA_5]1M8X(SX?\5-;VMJL:D(%@5<%02S$$\L['O4G[;G[<
MFG?L@W_PT\'VG@4:YXB^*_CR#PKX634-2:PTRWN70R-)>7@AF,"[%(15C=Y'
M(4+C<R]W\$[O]HF6QNKO]H6X\$1W4XC>QL/!B7;I:`EMZ//<L#<8^4!UBBR0
M24&0!<J-.<>5K02;6QXZ?V$OVBTU163_`(*.?$[[`+7'E^7:F<S;N#O*[=FW
M(V[=V>=V.*V/@?\`\$T_@/\`!_XAM\9->O=8\:^,I)EN9/$'BVY2X=;H,2;F
M-`H"2=!NYVA1MVU]%4R6=(6568`MT!;&:A86@FG;8?-(>!@`>E%%%=!($`]1
M7%_'?X"_#;]HWX=7WPP^*6@)?:9>KD,#MEMI1]R:)^J2*>01[@@@D'M**F48
MSBXR5TP/S`USX$?MT?\`!+WX@:GXT_9W2\\7?#J>X,]S9B(W".FT?\?=O'AX
MY%'R^?'A3@%N/DKW'X(?\%J/V:/'6E6UO\7+;4/!FJLQ2Y$MJ]W9@A22ZRQ*
M6"G;@!D!!8#GK7V48%;[Q[Y%>+?%?_@GC^Q]\9RUQXP^"FD073S&22^T2,Z?
M-(Q;<Q=K<IO+$G);).37G?5<10E>A+3^5[+T\BW.,MS8C_;=_8\D0./VF_`P
MW`$`^)[8=?J]87Q#_P""C?[%GPWT;^VM2_:`T'4,Y$=KH-S]OFD([!(-V/\`
M@6`>U>0R?\$,_P!DYW++XZ\=*I8E5_M2U.T9Z<VWX5L>"?\`@BU^QKX2U+^T
MM9A\3>(@'1H[;6-9"Q(5;)XMTBW`]"&)&.W--SS-Z*$5\V*T#Q_XS_\`!83X
MG?%OQ3'\(?V'?A3>W-_?S>3:ZQJ5D)KJ4E@H>&VR4C7D'S)B0`<LJUUG[$O_
M``2PU?1O&"?M'_MC:FVN^,)KU[Z+0KF<7$,-PS!EN+F3D33`@D*,HOR]2HQ]
M=?"C]G[X,?`W3FTSX1_#71_#\;IME;3K)4DE&21OD^^^"3C<3C-=A''LSSG-
M.G@I3DIUY\S[=$'-I9!&&"C=UQS3J**]$D\S^-/[(G[/G[0GBS0O'7Q8^&\.
MH:[X7CN8_#VOVM_<65_I\=PH6=(KFVDCE1'``90V#CI6[\+/@-\'?@I:W=I\
M)OA?H'AM;Z42WS:)I,5NUW)@#S)F10TKD`99RS'')KKZ*`"N0\<_`GX2?$;X
M@^$OBMXS^'^F:EXD\"7=U<^$-:NK?-QI4ES`UO.87&"OF1,58<@\$C(!'7T4
M`-CW;`&&#5+Q1X7\/>-?#M]X1\6Z'9:GI6IV<MIJ>F:C:I/;W<$BE)(I(W!5
MT925*D$$$@U?HH`\CTW]@[]CC1;ZUO\`3?V9?!`-A<1SZ7!)X=@>#394<.'M
M864QVK%PK,T2H6959BS`$>N8`Z"BB@`(!ZBN0\-_`?X1>$OBQXC^.?AKX>:7
M8>+?%UE96GB;7K6WV7&IQ6@<6RS$</Y8D<*2,X(&<``=?10`5C?$/P#X2^*G
M@36?AIX^T2'4]"\0:7<:=K.FW`)CN[6>-HY8FP0=K(S*?8ULT4`?/OP-_P""
M6O[!7[-7Q&T[XM?`S]FS1_#GB'28Y4T[4[.\NF>W62)HG"K)*RX,;,N,<`\8
MKZ"HHH`RO&O@CPC\1_"U]X'\?>&-/UK1M3MFM]2TG5K)+BVNHFX9)(I`5=3Z
M,"*X7X5_L=?LS_!'Q.WBWX4?!'P_H5]OG:VFL;(`6`F_UR6JG*VB2'YGCA"(
M[99@3S7I]%`!7,_$'X1_#OXJW?A^[^(?A.UU27PMXABUSPZ]R"38ZA%')''<
MI@CYU2:0#.1\YXKIJ*`./\4?`;X1^,OBIX:^.'B?X?:7?^+?!]K>V_A;7[JW
MWW&EQWBQK<B$DX0R+$BD@9P",X)!Z]`0H!'.*6B@`HHHH`*Y#P1\"/A)\-/'
M?BSXF^`?A]I>E^(/'=_;WGC#6+2V"W&JS00K!"TSG);9$H55X`&<#+$GKZ*`
M"N8\1?"#X=>*OB1X?^+NN^%+:Z\2>%+6]M_#NKR9\VQBO!&MRB<XQ((8PV0?
MN#&*Z>B@#S[1OV7?@)H/[0&H?M3Z1\*]'M?B%JVAC1]4\5VUMLNKRR#QL(I2
M#A^8HOF(W8B1<X4`>@T44`<]\3?A3\-?C+X6?P-\6/A]HGB?19IHY9M)\0:5
M#>6SNC!D<QS*REE8`@XR#R,5R?PG_9`_9P^!FN/XF^$OP:T+0[]A.L-S9VOS
M6L4TGF2P6^XG[-`S_.88MD9<EMN22?3:*`"N4\?_``4^%?Q2\2^'/%WQ`^'F
MD:UJ7A&_:^\-7NIV23/IUPP`,L.X?(^%7GL54CE01U=%`!1110!'1110`444
M5+W0!1115`%%%%);`%%%%,`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`
J****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`/_9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
